Medical technology giant Medtronic announced Tuesday its plans to acquire Scientia Vascular for $550 million, a strategic move designed to strengthen the company’s stroke treatment capabilities.
The Salt Lake City-based target company employs approximately 310 workers and specializes in manufacturing specialized guidewires and catheters designed for navigating blood vessels within the brain during medical procedures.
According to Medtronic, these specialized medical instruments will complement their current neurovascular product offerings without requiring significant integration challenges.
“The deal positions Medtronic with a full suite of products and supports procedures across both hemorrhagic and acute ischemic stroke,” stated Linnea Burman, who serves as senior vice president and president of Medtronic’s Neurovascular business division.
The medical device manufacturer anticipates completing the transaction during the first six months of fiscal year 2027.
Financial projections suggest the acquisition will have minimal impact on Medtronic’s adjusted earnings for 2027, with positive contributions expected in subsequent years.
While Medtronic confirmed that additional earn-out payments and milestone-based compensation could follow the initial purchase, company officials declined to provide specific details about these potential future payments.
